159 related articles for article (PubMed ID: 38473829)
1. The Predictive Value of Gut Microbiota Composition for Sustained Immunogenicity following Two Doses of CoronaVac.
Ng HY; Liao Y; Zhang R; Chan KH; To WP; Hui CH; Seto WK; Leung WK; Hung IFN; Lam TTY; Cheung KS
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473829
[TBL] [Abstract][Full Text] [Related]
2. Association between Gut Microbiota Composition and Long-Term Vaccine Immunogenicity following Three Doses of CoronaVac.
Zhang LN; Tan JT; Ng HY; Liao YS; Zhang RQ; Chan KH; Hung IF; Lam TT; Cheung KS
Vaccines (Basel); 2024 Mar; 12(4):. PubMed ID: 38675747
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events.
Ng SC; Peng Y; Zhang L; Mok CK; Zhao S; Li A; Ching JY; Liu Y; Yan S; Chan DLS; Zhu J; Chen C; Fung AC; Wong KK; Hui DS; Chan FK; Tun HM
Gut; 2022 Jun; 71(6):1106-1116. PubMed ID: 35140064
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
Front Immunol; 2022; 13():967051. PubMed ID: 36159863
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.
Netto LC; Ibrahim KY; Picone CM; Alves APPS; Aniceto EV; Santiago MR; Parmejani PSS; Aikawa NE; Medeiros-Ribeiro AC; Pasoto SG; Yuki EFN; Saad CGS; Pedrosa T; Lara AN; Ceneviva C; Bonfa E; Kallas EG; Avelino-Silva VI
Lancet HIV; 2022 May; 9(5):e323-e331. PubMed ID: 35338835
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Zeng G; Wu Q; Pan H; Li M; Yang J; Wang L; Wu Z; Jiang D; Deng X; Chu K; Zheng W; Wang L; Lu W; Han B; Zhao Y; Zhu F; Yu H; Yin W
Lancet Infect Dis; 2022 Apr; 22(4):483-495. PubMed ID: 34890537
[TBL] [Abstract][Full Text] [Related]
11. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
12. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
Han B; Song Y; Li C; Yang W; Ma Q; Jiang Z; Li M; Lian X; Jiao W; Wang L; Shu Q; Wu Z; Zhao Y; Li Q; Gao Q
Lancet Infect Dis; 2021 Dec; 21(12):1645-1653. PubMed ID: 34197764
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
Omma A; Batirel A; Aydin M; Yilmaz Karadag F; Erden A; Kucuksahin O; Armagan B; Güven SC; Karakas O; Gokdemir S; Altunal LN; Buber AA; Gemcioglu E; Zengin O; Inan O; Sahiner ES; Korukluoglu G; Sezer Z; Ozdarendeli A; Kara A; Ates I
Hum Vaccin Immunother; 2022 Nov; 18(6):2122503. PubMed ID: 36315843
[TBL] [Abstract][Full Text] [Related]
15. Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.
Zhao W; Chen W; Li J; Chen M; Li Q; Lv M; Zhou S; Bai S; Wang Y; Zhang L; Zhang P; Wang J; Zheng Q; Wu J
mBio; 2022 Jun; 13(3):e0018122. PubMed ID: 35475648
[TBL] [Abstract][Full Text] [Related]
16. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
Shinjo SK; de Souza FHC; Borges IBP; Dos Santos AM; Miossi R; Misse RG; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Kupa LVK; Ceneviva C; Seraphim JC; Pedrosa TN; Vendramini MBG; Silva CA; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Aug; 61(8):3351-3361. PubMed ID: 34664616
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
Front Immunol; 2022; 13():939311. PubMed ID: 36032136
[TBL] [Abstract][Full Text] [Related]
20. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong.
Peng Q; Zhou R; Wang Y; Zhao M; Liu N; Li S; Huang H; Yang D; Au KK; Wang H; Man K; Yuen KY; Chen Z
EBioMedicine; 2022 Mar; 77():103904. PubMed ID: 35248996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
